Senti Biosciences Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Senti Biosciences Holdings Inc (SNTI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Senti Biosciences Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 5M vs 35,556M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-98.7% annualized vs trailing 12 months), vs accelerating (+4.7%) for its tracked peer group.
- Growth: Senti Biosciences Holdings Inc generated -99.1% revenue growth year over year in Q2 2026, vs 14.0% for its tracked competitors combined.
- Profitability: Its -75,000.0% net margin compares with -117.5% for the peer group.
- Scale: Senti Biosciences Holdings Inc ranks #142 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
- Peer revenue share: Senti Biosciences Holdings Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.13M compares with $0.80M for the peer group (0.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SNTI Sales vs. its Competitors, Q2 2026
Senti Biosciences Holdings Inc reported revenue contraction of 99.05 % year on year in Q2 2026, below its competitors' combined revenue growth of 13.97 %.
With a net margin of -75,000.00 %, Senti Biosciences Holdings Inc reported lower profitability than its competitors (-117.50 %).
Senti Biosciences Holdings Inc generated 0.00 % of the combined sales of its peer group, down from 0.02 % a year earlier.
Senti Biosciences Holdings Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Senti Biosciences Holdings Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Senti Biosciences Holdings Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Senti Biosciences Holdings Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs -99.1% for Senti Biosciences Holdings Inc. Senti Biosciences Holdings Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Senti Biosciences Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Senti Biosciences Holdings Inc | - | - | - | Yes |
| Competitors combined (24) | ||||
| Similar-Size Competitors (9) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SNTI Stock Performance relative to its Competitors
SNTI Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Century Therapeutics inc | 282.9% | Outperformed |
| 2 | Artiva Biotherapeutics Inc | 282.9% | Outperformed |
| 3 | Fate Therapeutics Inc | 282.9% | Outperformed |
| 4 | Gilead Sciences Inc | 282.9% | Outperformed |
| 5 | Meiragtx Holdings Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Senti Biosciences Holdings Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Senti Biosciences Holdings Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Senti Biosciences Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Senti Biosciences Holdings Inc | 9.37 | 5.15 |
| Gilead Sciences Inc | 188,277.21 | 30,457.00 |
| Takeda Pharmaceutical Company Limited | 29,674.40 | 29,183.90 |
| Allegion Plc | 13,399.66 | 4,288.50 |
| Crispr Therapeutics Ag | 5,284.85 | 13.39 |
| Beam Therapeutics Inc | 2,528.88 | 156.04 |
| SUBTOTAL | 246,466.55 | 64,810.47 |
Sign in to see all competitors of Senti Biosciences Holdings Inc .
Sources: Senti Biosciences Holdings Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Senti Biosciences Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Senti Biosciences Holdings Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Crispr Therapeutics Ag | Named by the company | 85% |
| Gilead Sciences Inc | Named by the company | 85% |
| Sana Biotechnology Inc | Named by the company | 85% |
| Atara Biotherapeutics Inc | Named by the company | 85% |
| Intellia Therapeutics Inc | Named by the company | 85% |
| Vor Biopharma Inc | Named by the company | 85% |
| Beam Therapeutics Inc | Named by the company | 85% |
| Takeda Pharmaceutical Company Limited | Named by the company | 85% |
| Nkarta Inc | Named by the company | 85% |
| Caribou Biosciences Inc | Named by the company | 85% |
| Allogene Therapeutics Inc | Named by the company | 85% |
| Meiragtx Holdings Plc | Named by the company | 85% |
| Century Therapeutics inc | Named by the company | 85% |
| Artiva Biotherapeutics Inc | Named by the company | 85% |
| Fate Therapeutics Inc | Named by the company | 85% |
| Lyell Immunopharma Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Senti Biosciences Holdings Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Senti Biosciences Holdings Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Senti Biosciences Holdings Inc | Reportable 100.00 % |
| Allegion Plc | Allegion Americas 79.77 % |
| Century Therapeutics inc | Single reportable segment 100.00 % |
| Lyell Immunopharma Inc | Reportable segment 100.00 % |
| Caribou Biosciences Inc | Reportable 100.00 % |
| Lenz Therapeutics Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Senti Biosciences Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Senti Biosciences Holdings Inc | 9 | 132,077 | -1,270,872 |
| Gilead Sciences Inc | 188,277 | 1,791,588 | -190,588 |
| Takeda Pharmaceutical Company Limited | 29,674 | 620,934 | 14,657 |
| Allegion Plc | 13,400 | 322,444 | 49,519 |
| Crispr Therapeutics Ag | 5,285 | 66,627 | -2,244,473 |
| Beam Therapeutics Inc | 2,529 | 305,352 | -167,176 |
| PEERS TOTAL | 246,457 | 804,475 | -48,016 |
Sign in to see all peers for Senti Biosciences Holdings Inc .
Senti Biosciences Holdings Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Caribou Biosciences Inc | United States 94.16 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Senti Biosciences Holdings Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Senti Biosciences Holdings Inc's industry classification, broader than the peer set above. Market cap in millions of $.Senti Biosciences Holdings Inc ranks #142 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,320, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 227,218 | 25.72 % |
| 2 | Gilead Sciences Inc | 188,277 | 21.31 % |
| 3 | Moderna Inc | 81,799 | 9.26 % |
| 4 | Argenx Se | 63,476 | 7.19 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 142 | Senti Biosciences Holdings Inc | 9 | 0.00 % |
Market cap and industry share for the rest of Senti Biosciences Holdings Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-29.
Senti Biosciences Holdings Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 137 | Zivo Bioscience Inc | 13 | - |
| 138 | Biocardia Inc | 12 | -27.46 % |
| 139 | Brainstorm Cell Therapeutics inc | 10 | - |
| 140 | Intensity Therapeutics Inc | 10 | -40.74 % |
| 141 | Pluri Inc | 1,234 | 12.3% |
| 142 | Senti Biosciences Holdings Inc | 9 | -78.35 % |
| 143 | Futuretech Ii Acquisition Corp | 1,234 | 12.3% |
| 144 | Agomab Therapeutics Nv | 1,234 | 12.3% |
| 145 | Pharmacyte Biotech Inc | 1,234 | 12.3% |
| 146 | Liminatus Pharma Inc | 1,234 | 12.3% |
| 147 | Creative Medical Technology Holdings Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Senti Biosciences Holdings Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-29. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Senti Biosciences Holdings Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | 8.5x | 5.1x | +3.4x |
| Return on Equity | -1,539.97 % | industry aggregate | -1,536.54 % |
| Return on Invested Capital | -165.61 % | -6.17 % (avg) | -159.44 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Senti Biosciences Holdings Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | - |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | - | -25.37 % | -58.05 % | -96.62 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Senti Biosciences Holdings Inc's BCG Growth-Share Matrix
Relative market share (vs Senti Biosciences Holdings Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Senti Biosciences Holdings Inc falls in the Question Mark quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 10.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Senti Biosciences Holdings Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,320 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Senti Biosciences Holdings Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Senti Biosciences Holdings Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Senti Biosciences Holdings Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Senti Biosciences Holdings Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Senti Biosciences Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 1,536.5 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-98.7% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (45.80 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Senti Biosciences Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Senti Biosciences Holdings Inc | 0.79 | 1.24 | 0.31 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Takeda Pharmaceutical Company Limited | 0.09 | 0.56 | 0.58 |
| Allegion Plc | 0.32 | 1.86 | 0.99 |
| Crispr Therapeutics Ag | 2.51 | 16.26 | 0.16 |
| Beam Therapeutics Inc | 4.72 | 11.07 | 0.05 |
Sign in to see all peers for Senti Biosciences Holdings Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Senti Biosciences Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Senti Biosciences Holdings Inc | Q2 2026 | -99.1 % | - |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Takeda Pharmaceutical Company Limited | Q1 2025 | +0.1 % | -30.2 % |
| Allegion Plc | Q2 2026 | +12.7 % | +15.6 % |
| Crispr Therapeutics Ag | Q2 2026 | +1,041.4 % | - |
| Beam Therapeutics Inc | Q2 2026 | -94.2 % | - |
| PEERS TOTAL | +2.8 % | - |
Sign in to see all peers for Senti Biosciences Holdings Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Senti Biosciences Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Senti Biosciences Holdings Inc | Q2 2026 | - | - |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Takeda Pharmaceutical Company Limited | Q1 2025 | +3.1 % | +6.6 % |
| Allegion Plc | Q2 2026 | +14.1 % | +1.1 % |
| Crispr Therapeutics Ag | Q2 2026 | - | +453.8 % |
| Beam Therapeutics Inc | Q2 2026 | - | -23.0 % |
Sign in to see all peers for Senti Biosciences Holdings Inc .
Senti Biosciences Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Senti Biosciences Holdings Inc | - | - | - |
| Gilead Sciences Inc | - | - | - |
| Takeda Pharmaceutical Company Limited | 0.76% | 0.97% | 1.56% |
| Allegion Plc | 12.47% | 14.48% | 31.99% |
| Crispr Therapeutics Ag | - | - | - |
| Beam Therapeutics Inc | - | - | - |
Sign in to see all peers for Senti Biosciences Holdings Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Senti Biosciences Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Senti Biosciences Holdings Inc | - | 1.82 |
| Gilead Sciences Inc | - | 6.18 |
| Takeda Pharmaceutical Company Limited | 43.08 | 1.02 |
| Allegion Plc | 20.41 | 3.12 |
| Crispr Therapeutics Ag | - | 394.63 |
| Beam Therapeutics Inc | - | 16.21 |
| PEERS AVERAGE | - | 3.80 |
Sign in to see all peers for Senti Biosciences Holdings Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.